Kristen Olvera Riemenschneider

Global law firm Freshfields advised Eli Lilly and Company (“Lilly”) on its global strategic collaboration and licensing agreement, and equity investment in, InduPro Therapeutics (“InduPro”) to discover novel oncology treatments using InduPro’s proximity-guided platform. InduPro is a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases. Under the terms of the agreement, Lilly and InduPro will collaborate on up to three targets, for a total deal value of up to approximately $950m. Lilly will also make an equity investment in InduPro. Through the agreement, Lilly will gain access to InduPro’s proprietary AI/ML-enabled membrane interactomics (MInt) platform. InduPro will lead early discovery efforts, applying its proximity-guided platform to identify co-target pairs and advance bispecific and multispecific antibody programs emerging from the collaboration. The Freshfields team for Lilly included partner Kristen Riemenschneider, senior associate Zackory Burns, and associates Shannon O’Hara and Wolfgang Paulson advising on the collaboration and license agreement, and partner Calise Cheng and associates Jovian Marcelo and Anika Kharkar advising on the equity financing.

Jan 12

1 min

Freshfields Bruckhaus Deringer (“Freshfields”) advised international pharmaceutical company Grünenthal on its acquisition of Valinor Pharma and its product Movantik® (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. The transaction further expands Grünenthal's portfolio of established medicines and adds to the company's growing U.S. business. Read more about this transaction here. Freshfields worked closely with Grünenthal's global in-house team led by Sebastian Köhler (General Counsel), Benjamin Kaiser (Senior Legal Counsel & Head of Legal M&A) and Megan Renze (Senior Legal Counsel; Global Projects & Head of Legal LatAm). The Freshfields team comprised Corporate/M&A and Life Sciences Transactions: Partners Adam H. Golden (New York), Kristen Riemenschneider (D.C.) and Oliver J. Board (New York), Associates Ryan Taylor, Jake Silvers, Chinyere Obi, Nana Kessie, Laura Zhu and Tanny Kang (all New York) Executive Compensation and Benefits: Partner Nicole Foster, Senior Associate Jeffrey Anand, Associate Jordan Riley (all New York) Tax: Partner Joe Soltis (New York), Senior Associate Brendan Counihan (D.C.) Real Estate: Counsel Jeremiah Nelson (Silicon Valley), Associate Casey Hagen (New York) Finance: Partner Kyle Lakin (New York), Senior Associate Sonam Cheema (London) IP: Partner Mena Kaplan (New York), Senior Associate Daniel Spencer (D.C.) Antitrust, Competition and Trade: Partners Meghan Rissmiller (D.C.) and Rod Carlton (London), Special Counsel Charles Ramsey (D.C.), Associate Katie Kissinger (New York)

Jul 24

1 min

Thirty-four Freshfields partners have been selected to Lawdragon’s 500 Leading Dealmakers in America guide for 2026. The guide recognizes the M&A, corporate, securities, finance, private equity, tax, corporate governance and ESG leaders and other transactional lawyers handling the biggest deals. The partners recognized are: Andrea Merediz Basham – Corporate/M&A Elizabeth K. Bieber – Shareholder Engagement and Activism Defense Oliver J. Board – Corporate/M&A Ian N. Bushner – Private Capital Calise Cheng – Capital Markets Timothy J. Clark – Private Funds & Secondaries Chris DeCresce – Capital Markets Sebastian L. Fain – Corporate/M&A John A. Fisher – Corporate/M&A Erik Gerding – Capital Markets Adam H. Golden – M&A (Life Sciences) Matthew Goulding – Private Capital Alison M. Hashmall – Financial Services Regulatory Jenny Hochenberg – Corporate/M&A Paul Humphreys – Corporate/M&A Vinita Kailasanath – M&A (Life Sciences) Menachem Kaplan – IP and Tech Transactions Ethan Klingsberg – Corporate/M&A Denny Kwon – Corporate/M&A Kyle Lakin – Finance Michael Levitt – Capital Markets Allison Liff – Leveraged Finance Aly Love – Corporate/M&A Pamela L. Marcogliese – Capital Markets and Corporate Governance Jerome Ranawake – Finance Brian Rance – Finance Neal J. Reenan – Private Capital Damian Ridealgh – Private Credit and Capital Solutions Kristen Olvera Riemenschneider – M&A (Life Sciences) David Sewell – Financial Services Regulatory Sarah K. Solum – Capital Markets Phillip Stoup – Capital Markets Zheng 'Jonathan' Zhou – Corporate/M& Damien Zoubek – Corporate/M&A

Oct 20

1 min

Thirty-three Freshfields partners have been named to Lawdragon’s 500 Dealmakers in America guide. The guide recognizes the M&A, corporate, securities, finance, private equity, tax, corporate governance and ESG leaders and other transactional lawyers handling the biggest deals. The lawyers recognized are: Andrea Merediz Basham – Corporate/M&A Elizabeth Bieber – Shareholder Engagement and Activism Defense Oliver Board – Corporate/M&A Ian Bushner – Private Capital Timothy Clark - Private Funds & Secondaries Chris DeCresce – Capital Markets Sebastian Fain – Corporate/M&A John Fisher – Corporate/M&A Adam Golden – M&A (Life Sciences) Alison Hashmall – Financial Services Regulatory Jenny Hochenberg – Corporate/M&A Paul Humphreys – Corporate/M&A Valerie Ford Jacob – Capital Markets Vinita Kailasanath – M&A (Life Sciences) Menachem Kaplan – IP and Tech Transactions Ethan Klingsberg – Corporate/M&A Denny Kwon – Corporate/M&A Kyle Lakin – Finance Michael Levitt – Capital Markets Allison Liff – Leveraged Finance Pamela Marcogliese – Capital Markets and Corporate Governance Steven Matays – Tax Melissa Raciti-Knapp – Project Finance Jerome Ranawake – Finance Brian Rance - Finance Neal Reenan – Private Capital Damian Ridealgh – Private Credit and Capital Solutions Kristen Riemenschneider – M&A (Life Sciences) David Sewell – Financial Services Regulatory Sarah Solum – Capital Markets Paul Tiger – Corporate/M&A Zheng 'Jonathan' Zhou – Corporate/M&A Damien Zoubek - Corporate/M&A

Oct 18

1 min

Global law firm Freshfields advised Eli Lilly and Company (“Lilly”) on its global strategic collaboration and licensing agreement, and equity investment in, InduPro Therapeutics (“InduPro”) to discover novel oncology treatments using InduPro’s proximity-guided platform. InduPro is a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases. Under the terms of the agreement, Lilly and InduPro will collaborate on up to three targets, for a total deal value of up to approximately $950m. Lilly will also make an equity investment in InduPro. Through the agreement, Lilly will gain access to InduPro’s proprietary AI/ML-enabled membrane interactomics (MInt) platform. InduPro will lead early discovery efforts, applying its proximity-guided platform to identify co-target pairs and advance bispecific and multispecific antibody programs emerging from the collaboration. The Freshfields team for Lilly included partner Kristen Riemenschneider, senior associate Zackory Burns, and associates Shannon O’Hara and Wolfgang Paulson advising on the collaboration and license agreement, and partner Calise Cheng and associates Jovian Marcelo and Anika Kharkar advising on the equity financing.

Jan 12

1 min